Risk of stroke/systemic embolism, major bleeding, and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States medicare population: updated analysis

References

• Kannel WB, Benjamin EJ. Status of the epidemiology of atrial fibrillation. Med Clin North Am. 2008;92(1):17–40.
   PubMed Web of Science ®Google Scholar
• Colilla S, Crow A, Petkun W, et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112(8):1142–1147.
   PubMed Web of Science ®Google Scholar
• Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA. 2001;285(18):2370–2375.
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Calkins H, et al. AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and Heart Rhythm Society. J Am Coll Cardiol. 2019;74(1):104–132.
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Alpert JS, et al. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. Circulation. 2014;130(23):e199–e267.
   PubMed Web of Science ®Google Scholar
• Pradaxa. Package insert. Boehringer Ingelheim Pharmaceuticals; 2010.
   Google Scholar
• Xarelto. Package insert. Janssen Pharmaceuticals; 2011.
   Google Scholar
• Eliquis. Package insert. Pfizer Pharmaceuticals; 2012.
   Google Scholar
• Savaysa. Package insert. Daiichi-Sankyo Inc.; 2015.
   Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–2104.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Keshishian A, Li X, et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients. The ARISTOPHANES study. Stroke. 2018;49(12):2933–2944.
   PubMed Web of Science ®Google Scholar
• Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016;5(6):e003725.
   PubMed Web of Science ®Google Scholar
• Graham DJ, Baro E, Zhang R, et al. Comparative stroke, bleeding, and mortality risks in older medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation. Am J Med. 2019;132(5):596–604.
   PubMed Web of Science ®Google Scholar
• Kim MH, Lin J, Hussein M, et al. Cost of atrial fibrillation in United States managed care organizations. Adv Ther. 2009;26(9):847–857.
   PubMed Web of Science ®Google Scholar
• Sussman M, Menzin J, Lin I, et al. Impact of atrial fibrillation on stroke-related healthcare costs. J Am Heart Assoc. 2013;2:e000479.
   PubMed Web of Science ®Google Scholar
• Alkhouli M, Alqahtani F, Aljohani S. Burden of atrial fibrillation-associated ischemic stroke in the United States. J Am Coll Cardiol Clin Electrophysiol. 2018;4:618–625.
   Google Scholar
• Amin A, Keshishian A, Trocio J, et al. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivoraxaban compared with warfarin in the United States medicare population. Curr Med Res Opin. 2017;33(9):1595–1604.
   PubMed Web of Science ®Google Scholar
• Jensen PN, Johnson K, Floyd J, et al. Identifying atrial fibrillation from electronic medical data: a systematic review. Pharmacoepidemiol Drug Saf. 2012;21:141–147.
   PubMed Web of Science ®Google Scholar
• Crawford M, Church J, Akin B. CPI detailed report data for December 2014. Bureau of Labor Statistics; 2014 [cited 2017 Apr 5]. Available from: https://www.bls.gov/cpi/cpid1412.pdf
   Google Scholar
• Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–272.
   PubMed Web of Science ®Google Scholar
• Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the euro heart survey. Chest. 2010;138(5):1093–1100.
   PubMed Web of Science ®Google Scholar
• Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083–3107.
   PubMed Web of Science ®Google Scholar
• Lachenbruch PA. Comparisons of two-part models with competitors. Stat Med. 2001;20(8):1215–1234.
   PubMed Web of Science ®Google Scholar
• Deitelzweig S, Keshishian A, Li X, et al. Comparisons between oral anticoagulants among older nonvalvular atrial fibrillation. J Am Geriatr Soc. 2019;67:1662–1671.
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation. 2011;123(21):2363–2372.
   PubMed Web of Science ®Google Scholar
• Alberts M, Chen YW, Lin JH, et al. Risks of stroke and mortality in atrial fibrillation patients treated with rivaroxaban and warfarin. Stroke. 2020;51(2):549–555.
   PubMed Web of Science ®Google Scholar
• Deitelzweig S, Luo X, Gupta K, et al. Effect of apixaban versus warfarin use on health care resource utilization and costs among elderly patients with nonvalvular atrial fibrillation. J Manag Care Spec Pharm. 2017;23(11):1191–1201.
   PubMed Web of Science ®Google Scholar
• Jain R, Fu AC, Lim J. Health care resource utilization and costs among newly diagnosed and oral anticoagulant-naïve nonvalvular atrial fibrillation patients treated with dabigatran or warfarin in the United States. J Manag Care Spec Pharm. 2018;24(1):73–82.
   PubMed Web of Science ®Google Scholar
• Gilligan AM, Franchino-Elder J, Song X, et al. Comparison of stroke- and bleed-related healthcare resource utilization and costs among patients with newly diagnosed non-valvular atrial fibrillation and newly treated with dabigatran, rivaroxaban, or warfarin. Expert Rev Pharmacoecon Outcomes Res. 2019;19(2):203–212.
   PubMed Web of Science ®Google Scholar